Emerald Advisers LLC Increases Holdings in Travere Therapeutics, Inc. $TVTX

Emerald Advisers LLC raised its stake in Travere Therapeutics, Inc. (NASDAQ:TVTX) by 2.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,146,767 shares of the company’s stock after acquiring an additional 55,407 shares during the period. Travere Therapeutics makes up 1.6% of Emerald Advisers LLC’s portfolio, making the stock its 11th biggest position. Emerald Advisers LLC owned approximately 2.41% of Travere Therapeutics worth $51,308,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently modified their holdings of TVTX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Travere Therapeutics by 13.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,777 shares of the company’s stock valued at $1,029,000 after purchasing an additional 6,831 shares during the last quarter. Diversified Trust Co lifted its stake in shares of Travere Therapeutics by 43.5% in the second quarter. Diversified Trust Co now owns 22,899 shares of the company’s stock worth $339,000 after buying an additional 6,940 shares in the last quarter. KLP Kapitalforvaltning AS grew its holdings in shares of Travere Therapeutics by 30.0% during the second quarter. KLP Kapitalforvaltning AS now owns 19,500 shares of the company’s stock valued at $289,000 after buying an additional 4,500 shares during the last quarter. Aberdeen Group plc increased its position in shares of Travere Therapeutics by 86.6% during the second quarter. Aberdeen Group plc now owns 896,594 shares of the company’s stock valued at $13,270,000 after acquiring an additional 416,225 shares in the last quarter. Finally, AlphaQuest LLC raised its holdings in Travere Therapeutics by 881.6% in the 2nd quarter. AlphaQuest LLC now owns 35,250 shares of the company’s stock worth $522,000 after acquiring an additional 31,659 shares during the last quarter.

Travere Therapeutics Stock Up 1.1%

Shares of TVTX stock opened at $28.25 on Thursday. The company has a current ratio of 2.75, a quick ratio of 2.71 and a debt-to-equity ratio of 4.23. Travere Therapeutics, Inc. has a 12 month low of $12.91 and a 12 month high of $42.13. The stock has a market cap of $2.53 billion, a P/E ratio of -26.65, a P/E/G ratio of 1.01 and a beta of 0.85. The company has a 50 day simple moving average of $34.87 and a two-hundred day simple moving average of $26.75.

Travere Therapeutics (NASDAQ:TVTX) last issued its quarterly earnings data on Thursday, October 30th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.59. Travere Therapeutics had a negative net margin of 20.32% and a negative return on equity of 178.68%. The firm had revenue of $164.86 million during the quarter, compared to the consensus estimate of $106.09 million. During the same quarter in the previous year, the firm posted ($0.70) EPS. The company’s revenue for the quarter was up 162.1% compared to the same quarter last year. On average, research analysts expect that Travere Therapeutics, Inc. will post -1.4 earnings per share for the current year.

Insiders Place Their Bets

In other Travere Therapeutics news, insider Peter Heerma sold 4,980 shares of the firm’s stock in a transaction that occurred on Wednesday, December 24th. The shares were sold at an average price of $40.00, for a total transaction of $199,200.00. Following the sale, the insider owned 113,013 shares in the company, valued at approximately $4,520,520. This trade represents a 4.22% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jula Inrig sold 2,031 shares of Travere Therapeutics stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $40.18, for a total transaction of $81,605.58. Following the transaction, the insider directly owned 86,756 shares in the company, valued at $3,485,856.08. This represents a 2.29% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 333,226 shares of company stock valued at $11,564,056. 4.19% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

TVTX has been the topic of several recent analyst reports. Wall Street Zen upgraded Travere Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 13th. Piper Sandler increased their price objective on Travere Therapeutics from $26.00 to $35.00 and gave the company a “neutral” rating in a research report on Tuesday, November 4th. Guggenheim reissued a “buy” rating and issued a $49.00 target price on shares of Travere Therapeutics in a research report on Wednesday, January 14th. HC Wainwright restated a “buy” rating and set a $47.00 target price on shares of Travere Therapeutics in a research note on Friday, November 28th. Finally, TD Cowen reiterated a “buy” rating on shares of Travere Therapeutics in a research note on Friday, October 31st. Twelve investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Travere Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $38.86.

Travere Therapeutics Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.